A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
A phase 1/2 trial of FWD1802 in advanced solid tumours, run by Forward Pharmaceuticals Co., Ltd., now recruiting.
Overview
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. is a phase 1/2 interventional study registered as NCT06064812 by Forward Pharmaceuticals Co., Ltd., with 99 participants planned, started 2023-09-12 and due to reach its primary completion in 2026-03. Interventions recorded: FWD1802.
Similar pages
not linked directly; found by shared links- TrialA Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Shares Forward Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialAuger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.